The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Biotechnology
Berry Genomics Co.,Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.40% CNY8.70
America/New_York / 30 apr 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3 075.63 mill |
| EPS: | -1.130 |
| P/E: | -7.70 |
| Earnings Date: | May 17, 2024 |
| SharesOutstanding: | 353.52 mill |
| Avg Daily Volume: | 20.75 mill |
| RATING 2024-04-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.70 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.26x |
| Company: PE -7.70 | industry: PE 29.29 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY-1.705 (-119.60%) CNY-10.40 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 8.09 - 9.31 ( +/- 7.01%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY8.70 (1.40% ) |
| Volume | 26.95 mill |
| Avg. Vol. | 20.75 mill |
| % of Avg. Vol | 129.89 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 000710.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
000710.SZ
Berry Genomics Co.,Ltd, a genomics company, develops and commercializes technologies for the life sciences and clinical applications in China. The company offers NGS- based tests for various genetic diseases and cancers from preconception to adulthood; WES test for inherited pathogenic mutations in the GCH1 gene associated with the metabolic disease Dopa-responsive dystonia; CNV-Seq test for indicating translocation at the end of chromosomes 2 and 8; RNA-Seq test to demonstrate the photo-induced protein dimerization of plant cryptochromes; and WGS test for genome wide detection of DNA variants, including SNP, CNV, Indel, and SV. It serves approximately 2,000 hospitals throughout Mainland China, Hong Kong, Macao, and Taiwan. The company serves various organizations and facilities, including hospitals, research institutions, universities, and corporations. Berry Genomics Co.,Ltd has a partnership with Personalis, Inc. The company was founded in 2010 and is headquartered in Beijing, China.